Extension of Time to File SOU

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1581 (Rev 09/2005)

OMB No. 0651-0054 (Exp 12/31/2020)

---

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1581 (Rev 09/2005)

OMB No. 0651-0054 (Exp 12/31/2020)

SOU Extension Request
(15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

MARK: HAVESTUS (see, http://uspto.report/TM/88507992/mark.png)
SERIAL NUMBER: 88507992

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Glaxo Group Limited, having an address of
      980 Great West Road
      Brentford, Middlesex, TW89GS
      United Kingdom
      Email: trademarks@gsk.com
Proposed: Glaxo Group Limited, having an address of BB
      980 Great West Road
      Brentford, Middlesex, TW89GS
      United Kingdom
      Phone:
      Fax:
      Email: lbp.tm@gsk.com

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 12/31/2019.

For International Class 005:
Current identification: Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the first extension request.

The applicant's current Attorney Information:
      Merilee J. Arevalo      GSK

      LBP, 5.5A
      5 MOORE DRIVE
      RESEARCH TRIANGLE PARK, North Carolina 27709-3398
      United States
      Phone: 919-315-8204
      Fax: 919-315-3023
      The docket/reference number is 82796210
      Email: trademarks@gsk.com


The applicant's proposed Attorney Information:
      Merilee J. Arevalo      GSK

      LBP, 5.5A
      5 MOORE DRIVE
      RESEARCH TRIANGLE PARK, North Carolina 27709-3398
      United States
      Phone: 919-315-8204
      Fax: 919-315-3023
      The docket/reference number is 82796210
      Email: trademarks@gsk.com


Correspondence Information (current):
      MERILEE J. AREVALO
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gsk.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

Correspondence Information (proposed):
      Merilee J. Arevalo
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gsk.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Merilee J. Arevalo/      Date Signed: 03/03/2020
Signatory's Name: Arevalo, Merilee, J.
Signatory's Position: Trademark Counsel, GSK, NJ and PA bar member
Signatory's Phone: 919-315-8204

Mailing Address:
   GSK
   LBP, 5.5A
   5 MOORE DRIVE
   RESEARCH TRIANGLE PARK, North Carolina 27709-3398

RAM Sale Number: 88507992
RAM Accounting Date: 03/04/2020

Serial Number: 88507992
Internet Transmission Date: Wed Mar 04 10:50:04 ET 2020
TEAS Stamp: USPTO/ESU-XXX.XX.XX.X-202003041050044439
45-88507992-710c2546af0de8224b961602eeb1
38167e65c9aba5bc29f6227bf8948c1c836-DA-5
0034569-20200303110704651137